About the report

The analysis is split into:

    • The Drug Landscape – An analysis of all 1800+ assets in the Checkpoint database by drug phase and status, disease indication and more.
    • The Trial Landscape  – An analysis of the staggering 12000+ clinical trials tracked on Beacon Checkpoint and a deeper look into trends within the space, including top disease indications, phase distribution, and details on terminated or withdrawn trials.
    • The Commercial Market – A breakdown of deals in the checkpoint market by type, value and target, plus insights into the companies behind them.
    • The Future of the Checkpoint Space – A deep-dive into emerging targets, assets to look out for in 2024, and promising combination strategies.
    • Regulatory Announcements: A comprehensive review of every regulatory announcement from 2023.

You may also be interested in...

Harnessing STING & TLR: Current Developments, Clinical Trials, and Key Players in the Landscape

Find out more

The 2023 Checkpoint Landscape Review

Find out more

Beacon Checkpoint: PD-L1: An Endless Classic or Passing Fancy?

Find out more

Find out more

Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.

With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.

Discover a database tailored to your needs

Speak with our team

Our dedicated Checkpoint account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.


Get Started